Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia
详细信息 查看全文
- 作者：Wen Tian Suna ; Wei Xiangb ; Bee Ling Ngb ; Kartini Asarib ; Ralph M. Buntec ; Patrick J. Caseya ; Mei Wanga ; mei.wang@duke-nus.edu.sg" class="auth_mail" title="E-mail the corresponding author ; Charles Chuaha ; b ; charles.chuah.t.h@sgh.com.sg" class="auth_mail" title="E-mail the corresponding author
- 刊名：Experimental Hematology
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：44
- 期：3
- 页码：189-193.e2
- 全文大小：1690 K
文摘
- •
Isoprenylcysteine carboxylmethyltransferase inhibition enhances the effect of BCR-ABL tyrosine kinase inhibition.
- •
Cysmethynil, an isoprenylcysteine carboxylmethyltransferase inhibitor, augments tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells.
- •
The combination of cysmethynil and imatinib inhibits colony formation in primary chronic myeloid leukemia cells.
- •
The in vivo effects of the cysmethynil/imatinib combination are enhanced compared with the effects of either drug alone.
- •
Enhanced apoptosis may be caused by immediate and persistent inhibition of MAPK signaling.